JAK2 and glioma: Functional assays demonstrated that FCGBP promotes glioma cell aggressiveness by activating the JAK2/STAT3 signaling pathway.<h4>Conclusion</h4>This study highlights the critical role of FCGBP in glioma aggression and poor prognosis, indicating that it could serve as a potential therapeutic target.